Cingulate Inc banner

Cingulate Inc
NASDAQ:CING

Watchlist Manager
Cingulate Inc Logo
Cingulate Inc
NASDAQ:CING
Watchlist
Price: 6.81 USD 7.41% Market Closed
Market Cap: $52.4m

Relative Value

CING doesn't have a meaningful market cap.

The Relative Value of one CING stock under the Base Case scenario is hidden USD. Compared to the current market price of 6.81 USD, Cingulate Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CING Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

CING Competitors Multiples
Cingulate Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Cingulate Inc
NASDAQ:CING
52.4m USD 0 -2.4 -2.5 -2.4
US
Eli Lilly and Co
NYSE:LLY
966.3B USD 14.8 46.8 31.6 33.6
US
Johnson & Johnson
NYSE:JNJ
586.6B USD 6.2 21.9 15.2 18.7
CH
Roche Holding AG
SIX:ROG
290.5B CHF 4.7 30.9 13 15.2
CH
Novartis AG
SIX:NOVN
245.6B CHF 5.6 22.7 14 18
UK
AstraZeneca PLC
LSE:AZN
234.2B GBP 5.4 30.8 17.1 24.1
US
Merck & Co Inc
NYSE:MRK
298.1B USD 4.6 16.3 10.2 11.9
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.4 10.4 7.7 9
US
Pfizer Inc
NYSE:PFE
154.7B USD 2.5 19.9 7.4 9.9
US
Bristol-Myers Squibb Co
NYSE:BMY
123B USD 2.6 17.4 7.3 9
P/E Multiple
Earnings Growth PEG
US
Cingulate Inc
NASDAQ:CING
Average P/E: 24.1
Negative Multiple: -2.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
46.8
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
21.9
7%
3.1
CH
Roche Holding AG
SIX:ROG
30.9
29%
1.1
CH
Novartis AG
SIX:NOVN
22.7
15%
1.5
UK
AstraZeneca PLC
LSE:AZN
30.8
26%
1.2
US
Merck & Co Inc
NYSE:MRK
16.3
14%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.4
7%
1.5
US
Pfizer Inc
NYSE:PFE
19.9
26%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
17.4
17%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Cingulate Inc
NASDAQ:CING
Average EV/EBITDA: 46.8
Negative Multiple: -2.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
31.6
18%
1.8
US
Johnson & Johnson
NYSE:JNJ
15.2
2%
7.6
CH
Roche Holding AG
SIX:ROG
13
5%
2.6
CH
Novartis AG
SIX:NOVN
14
9%
1.6
UK
AstraZeneca PLC
LSE:AZN
17.1
11%
1.6
US
Merck & Co Inc
NYSE:MRK
10.2
7%
1.5
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.7
7%
1.1
US
Pfizer Inc
NYSE:PFE
7.4
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.3
-12%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Cingulate Inc
NASDAQ:CING
Average EV/EBIT: 101.4
Negative Multiple: -2.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
33.6
17%
2
US
Johnson & Johnson
NYSE:JNJ
18.7
6%
3.1
CH
Roche Holding AG
SIX:ROG
15.2
6%
2.5
CH
Novartis AG
SIX:NOVN
18
12%
1.5
UK
AstraZeneca PLC
LSE:AZN
24.1
24%
1
US
Merck & Co Inc
NYSE:MRK
11.9
6%
2
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9
8%
1.1
US
Pfizer Inc
NYSE:PFE
9.9
-1%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
9
-6%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett